INS 511

Referencias correspondientes a la pieza INS 511 

1. Prospecto autorizado del producto Dioxaflex Protect. Laboratorios Bagó 2015.

2. Yeomans ND, Tulassay Z, Juhanz L. Et Al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroideal antiinflamatory drugs. Acid Suppresion trial: Ranitidine vs Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT Study Group). N Engl J MED 1998; 338: 791-726.

3. Yeomans ND. A clinical approach to management of patients with non-steroideal anti-inflammatory gastropatty. Ital J Gastroenterol-Hepatol. 1999:31 Suppl 1: S89-92.

4. Latimer N, et al; National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009; 339: b2538.

5. Nissen SE, Nicholls S, Sipahi I et al, Effect of very high – intensity statin therapy on regression of coronary atherosclerosis:The ASTEROID trial JAMA 2006;295(13):1556-1565

6.De Vera MA, et al. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014 Oct;78(4):684-98.

7. Jones Peter H y col. Efcacy and safety of ABT – 335 (fenobric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis 201 (2009) 208-215

8. Keech AC et al. FIELD study investigator. Effects of long-term fenobrate therapy on cardiovascular events in 9795people with type 2 diabetes mellitus (FIELD Study): randomised controlled trial. Lancet 2005;366:1849-61

9. Keech AC et al. FIELD study investigator. Effect of fenobrate on the need for laser treatment for diabetic retinophaty (FIELD Study): a randomized control trial. Lancet 2007;370:1687-97

10. ACCORD Study Group. Effects of medical therapies on retinophaty progression in type 2 diabetes. N Engl. J Med 2010;363:233-44

11. Burgess D, et al. Effects of fenobrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenobrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation 2007;116:II_838 (abstract)

12. Kurtz TW, Gardner DG (1998) Transcription-modulating drugs: a new frontier in the treatment of essential hypertension. Hypertension 32:380–386

13. Organization WH: Denition, diagnosis and classication of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classication of diabetes mellitus. Edited by: WHO World Health Organization; 1999:1-28.

14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

15. Van Marwijk H, Allick G, Wegman F, Bax A, Riphagen II. Alprazolam for depression. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD007139. DOI: 0.1002/14651858.CD007139. pub2.

16. Julie Dopheide et al. The Psychopharmacology of Anxiety. Psychiatry Times. March 2002. Vol 19, Issue 3

17. Tranquinal: Información para prescribir

18. Rosembaum. J. The Development of Clonazepam as a Psychotropic: The Massachusets. General Hospital Experience. Clin. Psychiatry 2004, (suppl 5) 3-6

19. Escitalopram for the management of major depressive disorder: a review of its ecacy, safety, and patient acceptability. This article was published in the following Dove Press Journal: Patient Preferent and
adherence. 3 December 2012

20. Novo Humorap: Información para prescribir

21. Humorap: Información para prescribir

22. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. This article was published in the following Dove Press Journal: Patient Preferent and adherence. 3 decembrer 2012.

23. Calabrese JR1, Londborg PD, Shelton MD, Thase ME. Citalopram treatment of fluoxetine-intolerant depressed patients. J Clin Psychiatry. 2003 May;64(5):562-7.

24. These ME1, Ferguson JM, Lydiard RB, Wilcox CS. Citalopram treatment of paroxetine-intolerant depressed patients. Depress Anxiety. 2002;16(3):128-33.
25. Aguilera Zepeda JM, et al. Estudio prospectivo, comparativo, ciego, aleatorizado, con grupos paralelos para evaluar la efectividad de una combinación de glucosamina sulfato y meloxicam en Osteoartritis de cadera y rodilla. Actualizaciones en Reumatología. Inst Nac Rehab. México DF, Mayo 2008:1-22.

26. Gouze JN, et al. Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: inuence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum. 2001 Feb;44(2):351-60.

27. Yocum D, et al. Safety and efcacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med. 2000 Oct 23;160(19):2947-54.

28. Reginster JY, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001 Jan 27;357(9252):251-6.

29. Scaparrotta A, DÌ Pillo S, Attanasi M, Rapino D, Cingolani A, Consilvio NP. Verini M, Chiarelli F. Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multisciplinary Respiratory Medicine 2012, 7:13.

30. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Resiss TF, Becker A, Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 1998 279(15):1181-1186.

31. Wahn U, Dass B. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clinical Therapeutics 2008:30; 1026-1035.

32. Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Noonan G. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatric Pulmonology Jul 2009; 44(6):568-579.

33. Steinhubl S et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 202 Nov 20; 288 (19): 2411-20

34. Wiederkehr D, Berenson K, Casciano R, Stern L, Makenbaeva D, Mozaffari E, Lamerato L, Corbelli J. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation analysis in a nationally representative managed-care population. Curr Med Res Opin. 2009 Sep; 25(9):2317-25


El material incluido en este sitio ha sido concebido exclusivamente para los profesionales de la salud con fines informativos, y destinado a orientar sobre el uso adecuado de los medicamentos y a satisfacer sus necesidades de mayor información.

Todos los textos referidos a nuestros productos de venta bajo prescripción médica se corresponden a los lineamientos aprobados por la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).

Laboratorios Bagó le sugiere consultar siempre a un profesional de la salud calificado ante cualquier duda sobre una condición médica particular.

He comprendido y deseo ver la información

Consultas médicas: